Cognition Therapeutics (CGTX) Operating Income (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Operating Income of -$8.8 million for Q1 2026, up 35.99% year-over-year from -$6.5 million in Q1 2025, and up 35.51% quarter-over-quarter from -$13.7 million in Q4 2025.
Cognition Therapeutics (CGTX) Operating Income (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Operating Income for 7 consecutive years, with -$8.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 35.99% year-over-year to -$8.8 million; the TTM figure through Mar 2026 stood at -$42.8 million (up 20.13% YoY), while the FY2025 annual figure was -$47.8 million, up 11.43% from the prior year.
- Operating Income grew to -$8.8 million in Q1 2026 per CGTX's latest filing, from -$13.7 million in the prior quarter.
- Across five years, Operating Income topped out at -$6.4 million in Q3 2025 and bottomed at -$15.2 million in Q4 2023.
- Historically, Operating Income has averaged -$12.2 million across 5 years, with a median of -$13.1 million in 2022.
- Annual changes were most pronounced in 2022 — Operating Income tumbled 141.72% — and 2025, when it soared 55.92%.
- Cognition Therapeutics' Operating Income stood at -$12.2 million in 2022, then slipped by 24.37% to -$15.2 million in 2023, then climbed by 29.4% to -$10.7 million in 2024, then dropped by 27.49% to -$13.7 million in 2025, then jumped by 35.51% to -$8.8 million in 2026.
- Business Quant data shows CGTX's Operating Income at -$8.8 million in Q1 2026, -$13.7 million in Q4 2025, and -$6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | -7.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.74 Mn |
| Mar 31, 2026 | -8.82 Mn |
| Dec 31, 2025 | -13.67 Mn |
| Sep 30, 2025 | -6.38 Mn |
| Jun 30, 2025 | -13.98 Mn |
| Mar 31, 2025 | -13.78 Mn |
| Dec 31, 2024 | -10.72 Mn |
| Sep 30, 2024 | -14.46 Mn |
| Jun 30, 2024 | -14.68 Mn |
| Mar 31, 2024 | -14.10 Mn |
| Dec 31, 2023 | -15.19 Mn |
| Sep 30, 2023 | -14.75 Mn |
| Jun 30, 2023 | -11.82 Mn |
| Mar 31, 2023 | -8.97 Mn |
| Dec 31, 2022 | -12.21 Mn |
| Sep 30, 2022 | -12.63 Mn |
| Mar 31, 2022 | -9.41 Mn |
| Dec 31, 2021 | -11.81 Mn |
| Sep 30, 2021 | -5.22 Mn |
| Dec 31, 2020 | -4.12 Mn |